Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q1 2022 Earnings Conference Call May 16, 2022 8:00 AM ET Company Participants Tom Galassi - Investor Relations, LifeSci Advisors Chaim Lebovits - Chief Executive Officer Alla Patlis - Interim Chief Financial Officer Stacy Lindborg - Executive Vice President and Chief Development Officer Ralph Kern - President and Chief Medical Officer David Setboun - Executive Vice President and Chief Operating Officer Conference Call Participants David Bautz - Zacks Small-Cap ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact name of registrant as specified in it ...

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2021 Results Earnings Conference Call March 28, 2022 8:00 AM ET Company Participants Michael Wood - Investor Relations, LifeSci Advisors Chaim Lebovits - Chief Executive Officer Alla Patlis - Interim Chief Financial Officer Ralph Kern - President and Chief Medical Officer Stacy Lindborg - Executive Vice President and Chief Development Officer Conference Call Participants David Bautz - Zachs SCR Michelle Lorenz - Voices for ALS Operator Good day, ladies and ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ⌧ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |--------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------| | FOR THE TRANS ...

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q3 2021 Earnings Conference Call November 15, 2021 8:00 AM ET Company Participants Michael Rice - Investor Relations, LifeSci Advisors Chaim Lebovits - President & Chief Executive Officer Alla Patlis - Interim Chief Financial Officer Stacy Lindborg - Executive Vice President & Chief Development Office Ralph Kern - President & Chief Medical Officer David Setboun - Executive Vice President & Chief Operating Officer Conference Call Participants Michael Rabinowit ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact name of registrant as specified i ...

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q2 2021 Earnings Conference Call August 5, 2021 8:00 AM ET Company Participants Chaim Lebovits - President and CEO Dr. Ralph Kern - President and CMO Dr. Preetam Shah - EVP and CFO Dr. Stacy Lindborg - EVP and Head of Global Clinical Research Dr. David Setboun - EVP and COO Conference Call Participants David Bautz - Zacks Small Cap Research Operator Good day ladies and gentlemen and welcome to BrainStorm Cell Therapeutics’ Second Quarter 2021 Earnings Call. At ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact name of registrant as specified in its ...

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q1 2021 Earnings Conference Call April 26, 2021 8:00 AM ET Company Participants Michael Wood - IR, LifeSci Advisors Chaim Lebovits - President and CEO Dr. Stacy Lindborg - EVP and Head, Global Clinical Research Dr. Ralph Kern - President and Chief Medical Officer Dr. Preetam Shah - EVP and CFO Dr. David Setboun - EVP and COO Conference Call Participants David Bautz - Zacks Small Cap Research Operator Greetings. Welcome to BrainStorm Cell Therapeutics’ First Qu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact name of registrant as specified in it ...